Clinical study of sintilimab plus bevacizumab combined with transcatheter arterial chemoembolization in the treatment of advanced liver cancer

Tu Jiangjiang; Zhao Yanyi; Shi Yuanyuan; Xue Feng; Weng Jun; Li Siming

doi:10.3760/j.issn.1673-4777.2025.02.012

Abstract：Objective To investigate the clinical effect of sintilimab plus bevacizumab combined with transcatheter arterial chemoembolization(TACE)in the treatment of advanced liver cancer.Methods A total of 60 patients with advanced liver cancer admitted to the Affiliated Hospital of Guilin Medical University from November 2022 to December 2023 were selected.According to the random number table method,they were divided into the control group and the observation group,with 30 cases in each group.The control group was treated with TACE and bevacizumab,and the observation group was treated with sintilimab on the basis of the control group.The clinical efficacy,tumor markers,lymphocyte levels,prognosis and survival time and safety were compared between the two groups.Results The objective remission rate and disease control rate of the observation group were higher than those of the control group[66.7％(20/30)vs 40.0％(12/30),83.3％(25/30)vs 60.0％(18/30)](both P＜0.05).After treatment,the levels of tumor markers alpha-fetoprotein,carcinoembryonic antigen and carbohy-drate antigen 199 in the two groups were lower than those before treatment,and the levels of tumor markers in the observation group were lower than those in the control group(all P＜0.05).After treatment,the CD3+,CD4+,and CD4+/CD8+ratios in both groups were higher than those before treatment,and those in the observation group were higher than those in the control group;the CD8+level was lower than that before treatment,and that in the observation group was lower than that in the control group(all P＜0.05).The disease progression time,progression-free survival time and overall survival time of the observation group were higher than those of the control group[(6.1±1.4)months vs(4.9±1.4)months,(7.9±1.7)months vs(6.5±1.4)months,(11.2±2.1)months vs(9.7±2.0)months](all P＜0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P=0.739).Conclusion Sintilimab combined with bevaci-zumab combined with TACE has a good application in the treatment of advanced liver cancer,which can improve the short-term efficacy level,inhibit the level of tumor markers,improve the immune function of patients,prolong the prognosis and survival time of patients,and the treatment safety is good.